Cystic Fibrosis Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 As per the analysis conducted by Market Research Future (MRFR), the Global Cystic Fibrosis Market is expected to expand at a CAGR of 13.5% and is likely to acquire the market value of USD 12,943.1 Million by 2022.

Cystic fibrosis is a chronic, genetic disease that is bringing severe impact on the lives of about 70,000 people. As of now, the condition is not entirely curable. However, it can be partially cured with the help of particular medications and therapies. The cystic fibrosis market showed a rise in 2012 with the introduction of Kalydeco drug by Vertex pharmaceutical. Since then, there has been a continuous development of new medicines and therapies for treating cystic fibrosis. The financial backing of CFF is influential in the growth of the cystic fibrosis market worldwide.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1825 

COVID-19 is expected to bring a significant impact on the global market for cystic fibrosis. The outbreak has brought an adverse effect on the industry. The imposition of lockdown in various countries is likely to hamper the global fibrosis treatment market.

Market Dynamics

The rising prevalence of Cystic Fibrosis (CF) and the on-going research and development activities undertaken by the various government are expected to be significant factors that can grow the demand for cystic fibrosis diagnosis during the assessment period. The increasing participation of nonprofit organizations is projected to boost the market growth in the review period. The growing prevalence of CF is expected to enhance the demand for alternatives to treat the diseases, which is predicted to augment cystic fibrosis market size.

Drivers

Growing Innovation to Cure the Disease can boost the industry

The availability of personalized drug therapy and molecular prosthetics to cure cystic fibrosis is expected to be a significant cause that can drive the market during the forecast period. The rising awareness about the disease across the globe is predicted to grow the market in the coming tenure. Also, the increasing R&D investments made by the government of various countries is expected to enhance the cystic fibrosis medications that can grow the market.

Opportunities

Development of Pharmaceuticals and Biotechnological Sectors

The on-going development in the pharmaceuticals and biotechnological sector is expected to produce a significant opportunity that can augment the market during the forecast period.  

Restraints

Limited Opportunities to Hinder Market Growth

The presence of limited revenue opportunities and high expenses associated with the treatment are expected to be significant restraining that may have a negative impact on the cystic fibrosis test.

Challenges

Introduction of Generic Drugs is a Significant Challenge

The introduction of generic drugs and patient expiration are some of the major challenges that the market is expected to face during the review period.

Cumulative Growth Analysis

The Market is anticipated to grow in the Future

The industry is likely to grow in the coming period due to the growing product launching and technological innovation. Furthermore, the increasing participation of the government is anticipated to underpin the cystic therapeutics market during the review period.

Market Segmentation

By Treatment Method

Medication Segment to Lead the Cystic Fibrosis Market

Based on the treatment method, the global market for cystic fibrosis is segmented into devices, medication, and other treatments. The medication segment accounted for a market value of USD 2802.7million in 2016. Among all, the medication segment is anticipated to lead the global market during the forecast period.

Regional Analysis

North America to Acquire the Highest Market Share Due to High FDA Approval of Drugs for Cystic Fibrosis

Cystic fibrosis can occur in both genders as well as in all ethnic groups and races. However, the incidences of cystic fibrosis vary across the globe. Cystic fibrosis is more common among Caucasians. Hence the disease is more prevalent in North America, Europe, and Australia. However, cystic fibrosis can also affect Latinos, American Indians, African, and Middle Eastern populations.

North America is expected to dominate the global market due to the growing FDA approval of drugs for cystic fibrosis. The demand to cure the disease with the increasing integration of the latest technologies in the healthcare sector is expected to underpin the expansion of the regional market. Among all countries of North America, the United States is expected to witness the highest incidence rates of cystic fibrosis, thereby propelling the regional market. As per the records by the cystic fibrosis foundation, more than 30,000 patients have been affected with cystic fibrosis in the United States. About 1000 new cystic fibrosis cases are diagnosed each year in the US.  

Europe is largely affected by cystic fibrosis, which is expected to be a significant factor that can grow the regional market. According to the European Cystic Fibrosis Society (ECFS), considering the 26 major countries in Europe, more than 35,500 people were suffering from cystic fibrosis in 2014.  The region is likely to experience a rise in governmental support along with the growth in initiatives for R&D are further expected to fuel the regional market.

APAC is predicted to acquire a notable market share during the forecast period owing to the expanding geriatric population. The on-going development in the healthcare infrastructure is predicted to underpin the regional market in the assessment period. In addition, the R&D activities to find an apt solution to the disease is projected to strengthen the regional market.

The incidence of cystic fibrosis in the Middle East varies according to ethnic background. However, the CF prevalence in the Middle East is low as compared to the North American and European regions. There is no accurate CF prevalence number for the Northern African countries, but it is expected to be low due to the racial factor and no European genetic mixture.

Competitive Landscape

The increasing innovation of the product and the rising R&D is expected to offer various opportunities for market expansion in the coming period. Multiple players are likely to enter the market, thereby strengthening the competitiveness of the market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825 

Capsule Endoscopy Market to Witness Widespread Expansion During 2020-2027

 

Market Overview

Capsule Endoscopy market at Global level is a procedure that is used to get visual imaging of the inside area of intestines and other parts of the digestive tract. The reason why the market is getting into heights is that it is used to detect polyps, are there inflammatory bowel diseases, ulcers, and tumors of the intestine, especially the small intestine. The global capsule endoscopy market as per the registered forecasted periods is expected to attain a CAGR of 8.8% and is thought to reach USD 967.4 million by 2023.

With the growing world market of capsule endoscopy, there are certain risks and restraints to it such as complications of lack of skilled physicians that do hinder the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7355 

COVID 19 Analysis

As for the growing situation of coronavirus which the world is facing every day. The market of the global capsule endoscopy is not at its best. Due to the attention that has been all soaked up by the pandemic. It has caused other diseases and other problems to get suppressed beneath it. Other problems and diseases are now given less heed and importance. Cancer, pneumonia, jaundice, and are also not treated to an extent where they should be. Hence more and more medical issues are developing but not being cured which is steeping down the market of capsule endoscopy.

Market Dynamics

Drivers

The global capsule endoscopy market is growing tremendously in the global market due to the increasing small intestinal disorders and increasing geriatric population. The other valid region why the market is growing is due to the new cases of colon cancer that have been reported in America in 2018. Also, the population with the higher number of older people tend to have the propensity of gastrointestinal diseases and hence they need capsule endoscopy. This is why the global market is directly growing bigger in a much positive way.

Opportunities

The global capsule endoscopy market is growing tremendously in the global market and hence has various new opportunities to grow and develop. There are many new coming opportunities. For instance, according to the American Cancer Society in 2018, it is thought that about 97,220 new cases of colon cancer were seen and observed. The older population is growing with a higher tendency to get affected with gastrointestinal diseases and will eventually need capsule endoscopy which is most likely to affect the growth of global capsule lenders' copy market in a much broader sense and positive sense.

Restraints

Although the global capsule endoscopy market is growing tremendously, that doesn't always mean positively. When there are higher market growth levels, various risks, and complications hinder the growth. One of the reasons which stop the global market from growing is the lack of skilled physicians who constrain the growth of this market.

Value Chain Analysis

The global capsule endoscopy market is growing and is benefiting various people as it is used to detect polyps, many other inflammatory bowel diseases that are quite destructive to the abdomen. Other reasons which add value to the growing global market are the detection of ulcers and tumors of the small intestine which are the most prevalent diseases in youngsters as well as old age people. Usually, the reason behind the prevalence of such problems is due to the unhealthy lifestyle that has been adopted.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/capsule-endoscopy-market-1359 

CBD Oil (Cannabidiol Oil) Market Growth, Trends and Value Chain 2020-2027

 

Market Overview

Global CBD Oil Market, according to MRFR, is poised to grow at a CAGR of 38.45% to reach USD 3.78 Billion till 2024. The global demand for CBD oil is primarily driven by increasing research funding over the study timeframe for cannabinoid research.

COVID-19 Analysis

The outbreak of COVID-19 and the interventions introduced by a variety of governments, such as social distancing and lockout, have contributed to a deterioration of the market. Since January 2020, the food service industry and other food industries, such as the bakery, liquor and dairy industries, have seen a significant decrease in their revenue production. Several table utilities around the world were disrupted by the lockout and operators were concerned about cash flow and weathering storms.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7355 

Market Dynamics

Drivers

Growing Medical Awareness of Benefits to Drive Market Growth

Growing research and development efforts and financial funding for cannabinoid research from numerous private and government agencies. The discovery and production of cannabinoids for medicinal uses is funded by both private and government agencies. Cannabis has various medicinal properties that can treat different diseases. Over the evaluation period, this is expected to drive its production.

Because of its curing effects, the demand for cannabis oil (CBD) for medicinal and health uses is strong, which is the main factor driving market development. In addition, thanks to regulatory approvals, increasing product acceptance and usage is a major factor projected to fuel the market for goods infused with cannabis oil. In addition, the growing awareness of the medicinal advantages of cannabis oil has influenced individuals to purchase goods dependent on CBD, regardless of their cost.

Opportunities

Rise of Plant-based medicines to Create Growth Avenues for Key Players

As a result of the the number of social media influencers endorsing the benefits of cannabis, awareness campaigns from industry participants, and the application areas, cannabis oil has become the new consumer trend. Subsequently, the food portfolio is widening with growing product choices such as skincare, makeup, haircare, intimate lubricants, pharmaceuticals, gummies, tablets, flavoured drinks and other products. In recent years, plant-based medicine has witnessed considerable development. Moreover, the need for minimally manufactured and chemical-free medication has opened up a lucrative opportunity for the studied market to expand.

Restraints

Lack of legalization initiatives to Impede Market Growth

Business development may be hampered by the toxic effects associated with cannabis and rigid regulatory policies. In addition, some of the key factors limiting the development of the cannabidiol market are the prevalence of tight regulations and the high cost of CBD drugs. In addition, another primary factor hindering the development of the CBD industry is the lack of legalisation initiatives in many Asian and African countries.

Segmental Analysis

By Type

The leading segment, which is rising at the fastest CAGR to hit USD 2,092.97 million by the end of 2024, is Hemp-derived CBD oil. The differing amounts of tetrahydrocannabinol (THC) in hemp and marijuana account for the wide market share of hemp-derived CBD oil. Hemp is used for commercial uses for this cause, while hemp is cultivated for recreational and medical purposes.

By Application

With a 38.80 percent CAGR over the projected period, the cosmetic industry accounts for a large share. Increased legalisation and comprehensive CBD studies are growing their uses in the cosmetic industry, such as cosmetics products infused with CBD oil, as hemp-derived oils are proven to unclog pores, be anti-inflammatory and provide hydration.

Regional Analysis

Presence of Major Players Drives North America

When cannabis-based goods are gradually consumed, the Americas dominate the worldwide demand for CBD oil. Any of the key factors driving the region's development are the growing legalisation of medical cannabis in independent states of the U.S., the liberalisation of federal laws surrounding the same, and a general rise in the approval of cannabidiol for medicinal, health, and personal usage. In addition, for medicinal reasons, Canada has authorised the cultivation and selling of both CBD and THC potent marijuana. Therefore, the country's availability of CBD-based goods also promotes market growth in the field.

Germany to Drive Europe Market Growth

The European market for CBD oil has been divided into France, Germany, Italy, the United Kingdom, Russia and the rest of Europe. Due to the growing awareness of the medicinal uses of cannabis, Europe holds the second largest market share in the Western Europe region.

Rising Cosmetic Industry to Drive APAC

Asia-Pacific accounted for 9.16 percent market share as of 2018 and during the projected timeframe it was predicted to show the highest CAGR. The Asia Pacific market is expected to experience the fastest growth in the forecast period due to the establishment of hemp manufacturing plants, especially in China. China is Asia's biggest hemp producer and cultivates about half of the world's hemp output. In addition, players in end-use sectors such as personal care and cosmetics are striving to increase their profitability and revenue in developing economies. Therefore, the the attention of producers of cannabidiol-based products in Asia-Pacific countries and the the legalisation of cannabis for medicinal purposes in those countries are some of the key factors driving demand growth.

MEA to Witness Gradual Growth

Due to strict government policy, harmful effects associated with cannabis and the illicit use of marijuana, the Middle East & Africa is expected to see limited development.

Competitive Landscape

Mergers and Acuisitions to Remain Primary Focus of Market Players

There are many players competing in the global market for CBD Oil. Owing to the presence of a significant number of local and multinational firms, the global CBD oil market is heavily crowded. A vast variety of items on the market are available. The majority of businesses concentrate on cost-effective goods, while others have embraced merger tactics and strategic partnerships for business expansion. Any of the major companies, taking advantage of their good position and presence in the number of countries and regions around the world, have gained a large share of the global market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cbd-oil-market-7355 

Preclinical CRO Market Growth, Trends and Value Chain 2020-2027

 

Market Overview

Preclinical CRO Market is projected to record a CAGR of 8.14% to influence an earning level of USD 5,234.7 Million by the end of the forecast in 2024. A preclinical CRO brings the knowledge, experience, and skill essential to take a medical product or device from its clinical-stage to selling and distribution.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7274 

COVID-19 Analysis

With the present COVID-19 pandemic calamity, the world is conscious of life-saving drugs' criticality developed and rapidly brought to market. The drugs being brought to market result from a close partnership with the sponsor company, which works with a clinical research organization (CRO) that manages the clinical trials. Several drugs go through various development phases from the concept to the commercialization stage. A suitable CRO is deemed invaluable in the situation, especially to a sponsor company in its search to bring a novel drug to market. A poor performing CRO can cause a new drug's regulatory approval to be denied or delayed. As SARS-CoV-2 persists in its spread globally, several players are dedicated to arranging support for uncovering an active immune and prophylactic plan to back the biotech, pharmaceutical, and academic groups in advancing anti-viral medication and vaccines against SARS-CoV-2.

Market Dynamics

Drivers

Growth In Outsourcing Of Non-Core Function

The need to focus on core functions is projected to lead to an increased offloading of non-essential activities, thus boosting the preclinical CRO market growth.

Enhanced Abilities Of Preclinical Cros To Offer Additional Value-Added Services

The diversification and advancement of the additional value-added services is predicted to give the CRO preclinical market revenue a boost in the future.

Surging Number Of Drugs In The Preclinical Phase

The burgeoning volume of products in the preclinical testing phase is predicted to enhance the forthcoming period's preclinical CRO market size.

Economies Of Production And Scale

The ability to easily reach economies of production and scale is estimated to work out in favor of the preclinical CRO market in the impending period.

Opportunities

Opportunity For Medical Device Companies To Outsource Preclinical Trials

The demand for medical device testing has risen incrementally over the past few years, which is foreseen to be outsourced to preclinical CROs, thus motivating the global market in recent years.

Challenges

Scarcity Of Labour And High Labour Cost

The shortage of labor that is specialized related to requirements to the sector is estimated to create a restriction on the overall growth.

Structural Changes In The Industry

The changes in the market's overall structure are estimated to reduce the momentum for the preclinical CRO market development in the near future.

Segment Overview

By Service

The toxicology testing segment is anticipated to spearhead the global market and record a considerable CAGR to attain USD 2,476.28 Million by the conclusion of 2024. Growing demand for new drugs and chemicals and dynamic development in the biopharmaceutical and pharmaceutical sectors is anticipated to drive the preclinical CRO market growth. The bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies segment is anticipated to show a peak CAGR of 8.96% by 2024.

By Application

Oncology is likely to appear as the leading segment in the forthcoming period.

By End-User

The pharmaceutical and biopharmaceutical industries segment is foreseen to create an impetus for global market growth in the future.

Regional Analysis

Americas To Exert Dominance On Global Market

The Americas regional market for preclinical CROs was the preclinical CRO's prime market in 2018 and is expected to continue its strong influence throughout the review period.

European Regional Market Shows Market

The European regional market reported a vital stake and is projected to be the second-largest market during the forecast period. The snowballing outsourcing undertakings in Europe are driving the development of the region's preclinical CRO market. Germany reported for the principal market portion of 24.7% in 2018, and the national-level market is anticipated to touch a CAGR of 6.69% throughout the forecast period.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/preclinical-cro-market-7274 

Research report covers the 3D Bioprinting Market Forecasts and Growth, 2020-2027

 Global 3D Bioprinting Market share is projected to touch a value of USD 1,923.02 Million by 2023, states Market Research Future (MRFR) in its report. The market can display a CAGR of 24.59% during the forecast period due to its growing applications in tissue engineering and organ transplantation.

3D bioprinting encompasses an array of 3D printing methods to combine cells and biomaterials to produce biomedical parts. Although the technology is in high use for research and development purposes, its application in the production of tissues and organs is likely to garner high demand.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/869 

The prevailing pandemic, COVID-19, has generated the demand for companies to maintain a digital asset. In situations like these, the 3D printer aids to meet the requirement, which is expected to boost the 3D bioprinting market growth.

Market Dynamics

The cost-economical nature of 3D bioprinting is expected to brighten the bioprinting future. This is buttressed by the use of small implants and prosthetics used in the treatment of dental or craniofacial disorders. Furthermore, the presence of numerous players in the 3D bioprinting market can keep production costs low and augur well for the market in the forthcoming years.

However, lack of awareness of the technology and shortage of skilled professionals can act as growth deterrents in the market.

Drivers

Growing Demand for Organ Transplantation to Boost the Market

Growing demand for organ transplantation is projected to drive the market by 2023.  The rising investments in 3D bioprinting via public and private means to widen its scope is likely to boost the market growth. Moreover, the cost-effectiveness of 3D bioprinted products is expected to develop the industry in the forecast timeframe.

Opportunities

Growing Application of 3D Bioprinting in Cosmetic Industry to Offer Lucrative Opportunities

The extensive usage of 3D bioprinting in the cosmetic industry is expected to offer various growth opportunities to the key players. The growing R&D, partnerships, and acquisitions are likely to augment the market in the coming period.

Restraints

Lack of Expertise to Hinder Market Growth

One of the major factors hindering the market growth is the lack of expertise and awareness is expected to obstruct the market growth during the forecast period.

Challenges

Socioethical Concerns Due to the usage of 3D Bioprinted products

The application of bioprinted products inside human bodies can grow biosafety concerns, which may also question some religious beliefs that can hinder the market growth. In addition, the concerns associated with waste elimination is expected to further restrict the market growth.

Cumulative Growth Analysis

Market is Expected to Grow Significantly in the Forecast Period

The market is anticipated to grow significantly in the coming period, at a rapid pace. The on-going technical development, the growing awareness, and the increasing 3D bioprinting applications are predicted to underpin the trade expansion at a global front.

Market Segmentation

The 3D bioprinting market is segmented by technology, material, application, and end-user.

By Technology

Inkjet 3D Bioprinting Segment to Exhibit Higher CAGR

Based on technology, the global market for 3D bioprinting is segmented into inkjet 3D bioprinting, microextrusion bioprinting, magnetic 3D bioprinting, and laser-assisted bioprinting. Among all, the microextrusion bioprinting segment is projected to witness a CAGR of 25.24% during the forecast period. This can be attributed to its growing applications in bioprinting. On the other hand, inkjet 3D bioprinting can exhibit 26.44% CAGR owing to being a viable alternative for scaffold fabrication.

By Material

Hydrogels to Thrive at a CAGR of 26.63% by 2023

By material, the global market for 3D bioprinting is segmented into living cells, extracellular matrices, and hydrogels. The hydrogels segment is expected to generate USD 652.54 million by 2023 at a CAGR of 26.63% during the forecast period.

By Applications

Research Applications Segment to Exhibit Higher CAGR due to its Growing Application in Regenerative Medicines

Based on applications, the global market for 3D Bioprinting market is segmented into research and clinical applications. The research applications segment is expected to exhibit a  CAGR of 24.74% by 2023 owing to applications in 3D cell culture and regenerative medicine. The clinical applications segment is likely to hold the market value of USD 507.55 million by 2023 while expanding at a CAGR of 24.19% during the assessment period.

By End-Users

Pharmaceutical & Biotechnology Segment to Grow Due to Growing Demand for Personalized Medicines

Among end-users, the global market for 3D bioprinting market is segmented into pharmaceutical & biotechnology companies and research organizations & academic institutes. Pharmaceutical & biotechnology companies are projected to display a CAGR of 24.98% till 2023 owing to the trend in personalized medicines.

Regional Analysis

North America is expected to hold the Largest Market Share in the Global 3D Bioprinting Market

As per the 3D bioprinting industry analysis conducted by MRFR, the Americas is expected to acquire the market value of USD 689.91 million by 2023. This can be attributed to growing investments in research and development and the presence of advanced healthcare infrastructure. The demand for organ transplant is likely to rise to grow the regional market in the coming period. In addition, the on-going development of 3D printed pills, which can be customized as per the person’s age and body weight, is expected to offer various opportunities for expansion for the 3D bioprinting market.

The APAC is projected to acquire the market value of USD 507.18 million by 2023 at a CAGR of 27.25% during the forecast period. The APAC region is anticipated to grow at a rapid pace due to the development in 3D printing, incorporation of the latest technologies in the healthcare sector, and abundance of opportunities. In addition, increasing government funding to accelerate the pace of 3D printing technology is projected to augment the 3D bioprinting market size.

The Europe 3D bioprinting market is expected to acquire a market value of USD 649.91 million by 2023 due to the rising focus on health and wellness. Increased demand for cosmetic surgery can play a salient role in the market’s progress in the region. Furthermore, agreements between established players to expedite the evolution of technology can net novel results. This is exemplified by the deal signed between BASF SE and Poietis to improve skincare products by the former.

Competitive Landscape

Growing Initiatives to Expand Customer Base to Grow Competition

The growing collaboration and rising partnerships among key players is expected to strengthen the competitiveness of the global market for 3D bioprinting. The renowned players of the market are taking initiatives to grow their consumer base by incorporating innovation in their products.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/3d-bioprinting-market-869 

Companion Diagnostics for Oncology Market Scope Analysis 2020-2027

 Global Companion Diagnostics for Oncology Market was valued at USD 1,603.16 Million in 2019 and is expected to register a CAGR of 22.57% during the forecast period of 2020 to 2027.

Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area. The growing prevalence of cancer across the globe is increasing the preference for targeted therapy, which is affecting the demand for CDx tests. According to Cancer Research UK, there were 17 million new cases of cancer across the world in 2018, in which lung and breast cancer accounted for the largest share, followed by colorectal and prostate cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10422 

Major market players are focusing on various growth strategies such as product launches, product advancements, and business expansions to cater to the growing need for personalized medicine. These product launches and business expansion drive the growth of the companion diagnostics for oncology market. For instance, in March 2020, Thermo Fisher signed a strategic agreement with Janssen Services to co-develop a companion diagnostic product related to oncology, which will support clinical trial enrollment globally. Similarly, in March 2019, Roche launched the Ventana PD-L1 (SP142) Assay in Europe as the first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. Furthermore, in March 2019, Roche received the US FDA approval for its Ventana PD-L1 (SP142) assay approved as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the treatment with Tecentriq in combination with Abraxane.

Segment Analysis

 Global Companion Diagnostics for Oncology Market has been segmented based on products & services, technology, indication, and end user. The market, on the basis of products & services, has been segmented into assays, kits & reagents and software & services.

Based on technology, the global companion diagnostics for oncology market is segmented into polymerase chain reaction (PCR) and next-generation sequencing (NGS). The global market, on the basis of indication, has been segmented into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others.

 Regional Analysis

 Global Companion Diagnostics for Oncology Market, based on region, is segmented into four main regions, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is accounted for a major market share in 2019, whereas Asia-Pacific is projected to be the fastest-growing regional market during the forecast period.

 In the global companion diagnostics for oncology market, the Americas held the largest share of 37.3% in 2019. The market growth in the Americas is due to the high prevalence rate of cancer and rising healthcare expenditure. According, to the National Institutes of Health, it was estimated that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Europe acquired the second-largest market share in 2019. The Europe market is expected to register a sturdy growth rate during the forecast period due to the presence of a large number of companies, growing research and development activity to develop targeted drug therapy for a cancer patient, and the rising per capita income increasing the preference for personalized medicine. According to the European Journal of Cancer, there were around 3.9 million new cases and 1.9 million deaths from cancer in Europe in 2018. The increasing cancer population supports market growth in this region.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period. The rapid growth of the Asia-Pacific market is due to the growing number of cancer patients and rising presence of market players. According to the Global Cancer Observatory, around 1,157,294 cases of cancer were reported in India in 2018. Additionally, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the regional market. The Middle East and Africa accounted for the least market of USD 82.64 million in 2019. The companion diagnostics for oncology market in countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising drug discovery, and increasing preference for personalized medicines. Also, the growing number of hospitals, research laboratories, and increasing investment by healthcare companies in this region drives the growth of CDx in the Middle East & African countries.

Key Players

MRFR recognizes the following companies as the Key Players in the global Companion Diagnostics for Oncology Market— Agilent Technologies Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), BioMérieux SA (France), Foundation Medicine (US), Archer Dx (US), Qiagen (Germany), Thermo Fisher Scientific Inc. (US), and Amoy Dx (China) and Abbott Laboratories (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422 

 

 

 

 

 

Global Cardiopulmonary Resuscitation Market size and forecast, 2020-2027

Global Cardiopulmonary Resuscitation Market was valued at USD 1,603.16 Million in 2019 and is expected to register a CAGR of 10.50% during the forecast period of 2020 to 2027.

Cardiopulmonary resuscitation (CPR) is a lifesaving technique useful in many emergencies, including a heart attack or near drowning, in which someone's breathing or heartbeat has stopped. During a cardiac arrest, due to an insufficient supply of blood, the heart stops beating. In such conditions, blood circulation vital to sustaining life can be provided by constantly compressing the heart through a physical force applied to the patient’s chest. This rescue technique is termed cardiopulmonary resuscitation (CPR), which is employed in emergencies or conditions to protect the patient from fatal myocardial infarction or brain damage.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6789  

Global Cardiopulmonary Resuscitation Market is mainly driven by the increasing prevalence of heart and respiratory diseases, rising geriatric population, rise in government initiatives, increasing global incidence of cancer, and growing product approvals by major players. People worldwide are living longer. According to the World Health Organization, by 2050, the world’s population aged 60 years and older is expected to be 2 billion, up from 900 million in 2015. By 2050, there will be almost this many (120 million) living in China alone, and 434 million people in this age group worldwide. By 2050, 80% of all older people will live in low- and middle-income countries.

Market Dynamics

Heart disease is the leading cause of death in men and women globally. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. It further stated that in 2017, emergency medical services-assessed out-of-hospital cardiac arrest occurred in an estimated 356,461 Americans; emergency medical services treatment was initiated in 52%. The initial recorded cardiac rhythm was ventricular fibrillation, ventricular tachycardia, or shockable by an automated external defibrillator in only 18.7%. Adult survival to hospital discharge was 10.4%; 8.4% had good functional status at discharge. Furthermore, according to NHS England, the respiratory disease affects one in five people and is the third-biggest cause of death in England (after cancer and cardiovascular disease). According to a new Tulane University study published in The Lancet, chronic obstructive pulmonary disease (COPD) is widespread in China, with 8.6% of the country's adult population with almost 100 million people suffering from chronic lung disease. In addition, as per the World Health Organization, it is estimated that 54% of deaths from noncommunicable diseases in the Eastern Mediterranean Region are due to cardiovascular diseases. Deaths attributed to cardiovascular diseases (of total deaths) range from 49% in Oman to 13% in Somalia. The prevalence of cardiovascular diseases is due to sedentary lifestyles and common risk factors, such as hypertension (ranging from 28% in the UAE to 41% in Libya and Morocco); diabetes (ranging from 4% in the Islamic Republic of Iran to 19% in Sudan) and hypercholesterolemia (ranging from 14% in Lebanon to 52% in the Islamic Republic of Iran). Effective CPR can improve the survival rate of patients with cardiac and respiratory diseases. Application of CPR immediately can increase the survival rate of victims significantly. A study by the American Heart Association states that 70% of Americans feel helpless in cardiac emergencies as they are not aware of administering CPR.

The International Liaison Committee on Resuscitation (ILCOR) launched the first global “World Restart a Heart (WRAH)” initiative in 2018. The aim was to increase public awareness and improve the rates of bystander cardiopulmonary resuscitation (CPR) for victims of cardiac arrest.

Segmentation

Global Cardiopulmonary Resuscitation Market has been divided based on Product Type, Compressor Type, Application, and End User.

On the basis of Product Type, the market is bifurcated into piston CPR devices, load-distributing band (LDB), active compression-decompression (ACD) devices and impedance threshold device, extracorporeal techniques and invasive perfusion devices, and others. The piston CPR devices segment is expected to register the highest CAGR of 11.57% during the forecast period.

On the basis of compressor type, the market is bifurcated into manual CPR and automatic mechanical CPR. The automatic mechanical CPR segment accounted for a larger market share with a value of USD 101.6 million in 2019.

On the basis of application, the market is bifurcated into emergency departments, coronary & intensive care units, organ transplant facilities, air medevac units, and EMT rescue units. The EMT rescue units segment is expected to register the highest CAGR of 12.71% during the forecast period owing to the rise in the availability of a skilled workforce across the globe.

On the basis of end user, the market is bifurcated into hospitals and clinics, cardiac catheterization laboratories, organ transplant units, and others. The hospitals and clinics segment accounted for the largest market share at a value of USD 136.1 million in 2027. This large share can be attributed to the growing awareness of many cardiovascular disease and arrhythmia.

Regional Analysis

Global Cardiopulmonary Resuscitation Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to command the largest market share due to the rise in the prevalence of lifestyle diseases and heart diseases.

Europe held a substantial share in the global market. This can be attributed to the technological advancements, high disposable income, growing geriatric population, and favorable regulatory framework. According to the British Heart Foundation, around 7 million people are living with heart and circulatory disease in the UK, where 3.4 million are men and 3.5 million women.

Asia-Pacific is expected to command the third-largest share of the global market owing to the growing geriatric population, increasing chronic diseases, and elevated utilization of medical devices in healthcare. Rising awareness regarding medical devices and key measures taken by government bodies in the adoption of monitoring devices and improving emergency paramedical services are the other key drivers of the market in Asia-Pacific.

The cardiopulmonary resuscitation market in Middle East & Africa is expected to exhibit steady growth during the review period due to the increasing number of heart & respiratory diseases and rapidly developing healthcare infrastructure. For instance, according to the Dubai Health Authority, nearly 30% of the UAE population suffers from heart disease, which has emerged as a major killer; 32% of people suffer from high blood pressure, with high stress being a major contributor.

Key Players

The Prominent Players in the Global Cardiopulmonary Resuscitation Market are Stryker, Nihon Kohden Corporation, ZOLL Medical Corporation, Koninklijke Philips N.V., Vyaire Medical, Inc., General Electric Company, CPR Medical Devices, Inc., Michigan Instruments, Corpuls, SCHILLER, and Medtronic.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/cardiopulmonary-resuscitation-market-1348 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com